Clinical trials: Perimenopausal Bone Loss, open to volunteers
Osteoporosis
Orthorexia Nervosa in Postmenopausal Osteoporosis
A total of 64 female patients diagnosed with osteoporosis based on dual-energy X-ray absorptiometry (DXA) measurements performed within the last six months, and 64 age-matched healthy controls without osteoporosis, will be…
- Trial name
- NCT06947213
- Where
- Turkey (Türkiye)
- Volunteers
- 128 people
- Sponsor
- Beylikduzu State Hospital
Osteoperosis
The Investigation of the Effectiveness of Virtual Reality Applications in Postmenopausal Osteoporosis Patients
Osteoporosis is a progressive disease characterised by a decrease in bone mass, deterioration in bone microarchitecture, and increased fragility.
- Trial name
- NCT07231822
- Testing
- Conventional treatment, Virtual reality treatment
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Kirsehir Ahi Evran Universitesi
Osteoporosis, Postmenopausal Osteoporosis
Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?
Osteoporosis is a major cause of morbidity and fragility fractures in postmenopausal women. Bone mineral density (BMD) alone may not fully reflect fracture risk and skeletal fragility.
- Conditions
- Osteoporosis, Postmenopausal Osteoporosis, Frailty, Fragility Fractures
- Trial name
- LUMINOS (NCT07677072)
- Where
- Turkey (Türkiye)
- Volunteers
- 98 people
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
Osteoporosis Risk, Osteoporosis, Postmenopausal
Evaluation of Osteo-Buddy in Improving Osteoporosis Knowledge
This is a pilot randomised controlled trial (RCT) to evaluate the use of a Virtual Health Assistant (VHA) named Osteo-Buddy in improving the knowledge of osteoporosis in older women.
- Trial name
- NCT07034131
- Testing
- Osteo-Buddy, Usual Care
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- SingHealth Polyclinics
Menopausal Osteoporosis, Bone Markers
COMPASS - COpenhagen MenoPAuSe Study
During menopause, estrogen levels drop while the level of another hormone - LH (luteinizing hormone) substantially increases. This hormonal shift is linked to bone Loss and other complications.
- Trial name
- COMPASS (NCT07254429)
- Testing
- Triptorelin 11.25 mg, Sodium Chloride 0.9%, Estradiol (E2)
- Where
- Denmark
- Volunteers
- 192 people
- Sponsor
- Martin Blomberg Jensen
Osteopenia, Osteoporosis
Calcium-Rich Food Versus Calcium Carbonate for Bone Health
This study will compare adherence, tolerability, safety, and treatment satisfaction between a calcium-rich food and a traditional calcium carbonate supplement in women ages 40 to 90 who are at increased risk for osteoporosis.
- Conditions
- Osteopenia, Osteoporosis, Bone Health in Perimenopausal Women, Menopause Related Conditions
- Trial name
- NCT07763509
- Testing
- 500 mg calcium from milk-derived minerals, Calcium Carbonate 500 MG
- Where
- United States
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- Cornell University
Circadian Rhythm Disorders, Osteoporosis
Chronotherapeutic Optimization of Teriparatide Administration in Postmenopausal Osteoporosis
This is a randomized, controlled, and exploratory study designed to evaluate the chronotherapeutic effects of teriparatide administration in postmenopausal osteoporosis.
- Trial name
- NCT06951776
- Testing
- Morning administration group of teriparatide, Evening administration group of teriparatide
- Volunteers
- 28 people
- Sponsor
- Peking University Third Hospital
Osteoporosis, Postmenopausal, Osteoporotic Fractures
Evaluation of a Decision Analysis Model in the DASH-Osteo Decision Aid.
Fragility fractures, often caused by low bone mineral density, are a major health concern for postmenopausal women. One way to prevent these fractures is by taking medication, but deciding whether to start treatment can be…
- Conditions
- Osteoporosis, Postmenopausal, Osteoporotic Fractures, Diphosphonates, Fracture Risk Assessment
- Trial name
- DASH-Osteo (NCT07120854)
- Testing
- Decision aid with decision analysis model, Decision aid alone, Usual Care
- Where
- Spain
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Osteoporosis, Postmenopausal
Vascular Function, Sarcopenia and Pain in Postmenopausal Osteoporosis
This study aims to follow a cohort of osteoporotic patients treated with anti-osteoporotic drugs and to evaluate the impact of these treatments on the osteoporosis-cardiovascular-sarcopenia triad and on pain.
- Trial name
- VASCO (NCT05228262)
- Testing
- Cohort follow-up
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Clermont-Ferrand
Osteoporosis, Postmenopausal
Mechanisms of Anabolic Osteoporosis Therapy
The aim of this study is to investigate the effect of romosozumab on bone cells during early and late phases of treatment.
- Trial name
- NCT05688969
- Testing
- early versus late biopsy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Massachusetts General Hospital
Osteoporosis, Postmenopausal Osteoporosis
AGE Burden and Response to Antiresorptive Therapy in Osteoporosis
Osteoporosis is a common condition that increases the risk of bone fractures. Although antiresorptive treatments such as bisphosphonates and denosumab are effective in increasing bone mineral density, some patients continue to…
- Trial name
- NCT07329543
- Volunteers
- 240 people
- Sponsor
- Bursa City Hospital
Osteoporosis, Osteoporosis Postmenopausal
Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients
This study is a prospective, randomized, controlled clinical trial comparing the efficacy of a 24-month cyclic therapy regimen (6 months of Romosozumab followed by 6 months of Denosumab, repeated for two years) versus a…
- Trial name
- NCT06938152
- Testing
- Romosozumab followed by Denosumab, Romosozumab and Denosumab Cycle Therapy
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- National Taiwan University Hospital
Menopause, Perimenopausal Disorder
Virtual perI-/Menopause Registry of AusTrALia
13 million (50.7%) Australians are born with ovaries, 14% (~3 million) are currently aged 40-59 yrs, \& all such who live to midlife will experience menopause, defined as >12 months without a period.
- Conditions
- Menopause, Perimenopausal Disorder, Postmenopausal Symptoms, Health Knowledge, Attitudes, Practice
- Trial name
- VITAL (NCT06487130)
- Testing
- N/A Observational Registry
- Where
- Australia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Bespoke Clinical Research
Osteoporosis in Post-menopausal Women
Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility Fractures
The aim of this clinical trial is to investigate the effectiveness of romosozumab started without stopping denosumab in patients diagnosed with postmenopausal osteoporosis with a very high risk of fragility fractures and who is…
- Trial name
- MORD (NCT06720350)
- Testing
- Romosozumab and Denosumab Combination Therapy, Romosozumab Prefilled Syringe [Evenity], Denosumab (Prolia)
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Marmara University
Postmenopausal Osteoporosis, Low Bone Mass
Study of TST002 Injection in Postmenopausal Women With Osteoporosis or Low Bone Mass
This is a randomized, double-blind, placebo- and active-controlled Phase II study evaluating the efficacy and safety of TST002 injection (a humanized monoclonal antibody) in postmenopausal women with osteoporosis or low bone…
- Trial name
- NCT07806331
- Testing
- Denosumab
- Volunteers
- 110 people
- Sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
Osteoporosis
Romosozumab and Denosumab, Alone or Combined, in Postmenopausal Osteoporosis
Osteoporosis is a lifelong chronic condition requiring long-term management. Conventional first-line anti-resorptive therapies often yield slow BMD improvement and may plateau after years of treatment.
- Trial name
- NCT07283887
- Testing
- Denosumab, Romosozumab
- Where
- Taiwan
- Volunteers
- 90 people
- Sponsor
- National Taiwan University Hospital
Osteoporosis, Postmenopausal, Osteopenia
High-Intensity Laser Therapy and Physiotherapy for Bone Health in Postmenopausal Women: A Randomized Trial
The goal of this clinical trial is to learn if adding high-intensity laser therapy (HILT) to a physiotherapy programme helps bone health in women after menopause who have low bone density (osteopenia or osteoporosis).
- Trial name
- NCT07734922
- Testing
- High-Intensity Laser Therapy, Standardised Physiotherapy Programme
- Where
- Romania
- Volunteers
- 40 people
- Sponsor
- Iuliu Hatieganu University of Medicine and Pharmacy
Postmenopausal Osteoporosis
StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis
Denosumab (Dmab) is a treatment for postmenopausal osteoporosis. However, its withdrawal is associated with a rebound phenomenon associated with an unexpected increased risk of vertebral fractures.
- Trial name
- SAFEST (NCT06767150)
- Testing
- a second infusion of ZOL when crosslaps levels reach 300 pg/mL, a rescue second infusion at month-12 (standard traitment)
- Where
- 17 sites in France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Toulouse
Postmenopausal Osteoporosis
Romosozumab and Denosumab Combination Therapy for Osteoporosis
In this research study, the investigators want to learn more about the effect of two different FDA-approved medications in the treatment of osteoporosis.
- Trial name
- NCT07909304
- Testing
- Romosozumab, Romosozumab and Denosumab
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Perimenopausal Bone Loss
Prunes Preventing Bone Loss in Perimenopause
Dietary interventions of prune consumption during the transmenopausal period are innovative methods to prevent bone loss. Modern medicine does not intervene to prevent or attenuate this highly vulnerable period of bone loss…
- Trial name
- Prune-UP (NCT07120997)
- Testing
- Prunes, Calcium supplement, Vitamin D Supplement
- Where
- United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Penn State University